The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

Blood - United States
doi 10.1182/blood.v126.23.3877.3877
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising From Follicular Lymphoma in Asian Patients Treated in the Rituximab Era

Scientific Reports
Multidisciplinary
2020English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Assessment Index of Clinical Transformation From Follicular Lymphoma (Fl) to Diffuse Large B-Cell Lymphoma (Dlbcl) in the Rituximab Era

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Multicentre Study of Primary Breast Diffuse Large B-Cell Lymphoma in the Rituximab Era

British Journal of Haematology
Hematology
2014English

Prognostic Nomogram for Overall Survival in Patients With Diffuse Large B‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Prognostic Significance of Serum Immunoglobulin Paraprotein in Patients With Diffuse Large B Cell Lymphoma

British Journal of Haematology
Hematology
2017English

The Negative Prognostic Significance of Serum Immunoglobulin Paraprotein in Patients With Diffuse Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy